# Zydus Lifesciences (ZYDUSLIFE) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/zyduslife

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,197.9
- Change: +0.41%
- As of: 2026-11-06
- 1D return: +0.41%
- 5D return: -3.82%
- 1M return: +7.72%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

As of 2026-11-06, ZYDUSLIFE trades at ₹1197.90, holding a position in the upper-middle portion of its 20-day range (+60.3%) and near the top of its 252-day range (+84.1%). The stock remains technically bullish across daily, weekly, and monthly horizons, with price trading above all key moving averages (20, 50, 200 SMA; 20, 50 EMA) and the Supertrend indicator. However, trend conviction is currently weak on the daily timeframe, evidenced by an ADX of 10.5, suggesting consolidation rather than strong directional momentum. This contrasts with established trends on the weekly (ADX 32.76) and monthly (ADX 32.93) charts.

Participation shows mixed signals: while a significant volume-driven downward anomaly occurred on 2026-11-04 (-4.2% return, volume ratio 3.58), recent price action has stabilized. A Harami pattern formed on 2026-11-06 indicates potential indecision or pause after recent moves. Immediate resistance lies just above at ₹1201.95 (0.34%), with further levels at ₹1207.93 and ₹1222.87. Support is located at ₹1189.97 (pivot, -0.66%) and ₹1175.03 (low, -1.91%). The stock is currently experiencing a minor drawdown of -3.8% from its recent high, with annualized volatility at +24.6%.

- Trend Structure: Bullish across all timeframes (price above SMAs/EMAs/Supertrend), but daily trend strength is weak (ADX 10.5) compared to established weekly (ADX 32.76) and monthly (ADX 32.93) trends.
- Price Positioning: Trading at ₹1197.90, situated in the upper-middle of the 20-day range (+60.3%) and near the upper end of the 252-day range (+84.1%).
- Key Levels: Immediate resistance at ₹1201.95 (0.34% above); next resistance at ₹1207.93 (0.84% above). Primary support at ₹1189.97 (pivot, -0.66% below); secondary support at ₹1175.03 (low, -1.91% below).
- Momentum & Risk: Recent extreme volume-driven downward move on 2026-11-04 (-4.2%, volume ratio 3.58) suggests selling pressure. Current drawdown is -3.8% from highs; annualized volatility is +24.6%.

- Harami
- Outside Bar
- Bullish Engulfing Reversal

### News Context

Zydus Lifesciences reported Q2FY27 results on November 4, 2026, revealing a divergence between top-line growth and bottom-line profitability. Revenue from operations rose 29.2% year-on-year to ₹7,909.6 crore, driven by international markets and a 76% surge in consumer wellness sales. However, consolidated net profit fell 26.6% to ₹925.5 crore, as total expenses increased sharply to ₹6,806.6 crore, including ₹657.3 crore in research and development spending. EBITDA declined by 6% despite the revenue expansion.

Following these results, brokerages issued positive recommendations. Choice Institutional Equities assigned a 'Buy' rating with a target price of ₹1,400 on November 5, while Prabhudas Lilladher issued an 'Accumulate' recommendation with a target of ₹1,191 on November 6. Additionally, Nuvama Wealth included Zydus Lifesciences in its Diwali stock picks for Muhurat Trading on November 4, citing attractive valuations and improving risk-reward prospects based on technical structures.

- Q2FY27 financials: Revenue grew 29.2% YoY to ₹7,909.6 crore, but net profit fell 26.6% to ₹925.5 crore due to rising expenses (₹6,806.6 crore) and R&D spend of ₹657.3 crore.
- Operational highlights: Pharmaceuticals segment accounted for 83% of sales; consumer wellness sales surged 76%; US FDA accepted pembrolizumab biosimilar application and Saroglitazar advanced through Phase III trials.
- Analyst views: Choice Institutional Equities set a 'Buy' rating with a ₹1,400 target (Nov 5); Prabhudas Lilladher set an 'Accumulate' rating with a ₹1,191 target (Nov 6).
- Market positioning: Nuvama Wealth selected Zydus Lifesciences for Muhurat Trading on Nov 4, citing attractive valuations and extreme bearish foreign-investor positioning.

- [Accumulate Zydus Lifesciences; target of Rs 1191: Prabhudas Lilladher](https://www.moneycontrol.com/news/business/stocks/accumulate-zydus-lifesciences-target-of-rs-1191-prabhudas-lilladher-14072576.html)
- [Buy Zydus Lifesciences; target of Rs 1400: Choice Institutional Equities](https://www.moneycontrol.com/news/business/stocks/buy-zydus-lifesciences-target-of-rs-1400-choice-institutional-equities-14071060.html)
- [Zydus Lifesciences Q2 net profit falls 26.6% to Rs 925.5 crore](https://economictimes.indiatimes.com/markets/stocks/earnings/zydus-lifesciences-q2-net-profit-falls-26-6-to-rs-925-5-crore/articleshow/135555960.cms)
- [Zydus Q2 profit falls 27% despite 29% revenue growth; consumer wellness sales surge 76%](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-q2-profit-falls-27-despite-29-revenue-growth-consumer-wellness-sales-surge-76/articleshow/135541093.cms)
- [Diwali 2026: Stocks to buy for Samvat 2083: Adani Energy, Coforge, PNB, Zydus, KDDL - 5 shares for Muhurat Trading](https://www.livemint.com/market/stock-market-news/diwali-2026-stocks-to-buy-for-samvat-2083-adani-energy-coforge-pnb-zydus-kddl-5-shares-for-muhurat-trading-11793785141234.html)

### What Changed

Zydus Lifesciences has signaled active engagement with the institutional community through two upcoming investor conferences in Mumbai. On November 5, 2026, the company notified the NSE and BSE of its participation in the Avendus Spark Investor Conference on November 17, 2026, and the JM Financial 'India Xchange 2026' conference on November 18, 2026. These filings indicate a scheduled outreach to analysts and investors later this month.

In parallel, Prabhudas Lilladher issued an 'Accumulate' recommendation for the stock, assigning a price target of ₹1,191. This analyst note suggests potential upside from current levels, providing a specific valuation reference point for retail investors. The company’s operational profile and exchange listing remain unchanged.

- Corporate Engagement: Zydus Lifesciences will participate in the Avendus Spark Investor Conference (Nov 17, 2026) and JM Financial's India Xchange 2026 (Nov 18, 2026), both in Mumbai, as announced on Nov 5, 2026.
- Analyst View: Prabhudas Lilladher assigned an 'Accumulate' rating with a price target of ₹1,191, indicating expected upside from current trading levels.
- Continuity: The company’s core business profile and NSE listing status remain stable with no structural changes reported.

- [Accumulate Zydus Lifesciences; target of Rs 1191: Prabhudas Lilladher](https://www.moneycontrol.com/news/business/stocks/accumulate-zydus-lifesciences-target-of-rs-1191-prabhudas-lilladher-14072576.html)
- [Zydus Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Cadilahc_05112026191417_Investorconference05112026.pdf)
- [Zydus Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Cadilahc_05112026192606_Investorconference05112026_1.pdf)

### Official Filings

Zydus Lifesciences reported a divergence in its Q2 FY27 results, with revenue from operations rising 29% year-on-year to ₹79,096 million, while net profit declined 27% to ₹9,255 million. EBITDA fell 6% to ₹18,945 million, maintaining a 24.0% margin. The company highlighted strong growth in Consumer Wellness (up 76%) and North America Formulations (up 21%). On the operational front, Zydus completed the acquisition of Sterling Biotech’s API business on November 2, 2026, and received USFDA approval for a transdermal product following inspections at its Ahmedabad and Moraiya facilities. Governance-wise, the Board appointed Walker Chandiok & Co LLP as statutory auditors for a five-year term starting after the 32nd AGM, replacing Deloitte Haskins and Sells LLP due to mandatory rotation rules. Additionally, the company confirmed the completion of a share buyback in June 2026, extinguishing 8,730,158 shares for ₹11,063 million.

- {'detail': 'Revenue increased 29% y-o-y to ₹79,096 million; Net Profit decreased 27% to ₹9,255 million; EBITDA margin held at 24.0%.', 'metric': 'Q2 FY27 Financial Performance'}
- {'detail': 'Completed acquisition of Sterling Biotech’s API business on November 2, 2026; secured USFDA approval for a transdermal product on October 21, 2026.', 'metric': 'Strategic Acquisitions & Regulatory Milestones'}
- {'detail': 'Appointed Walker Chandiok & Co LLP as statutory auditors for a five-year term (FY27–FY32); completed share buyback of 8,730,158 shares for ₹11,063 million in June 2026.', 'metric': 'Governance & Capital Structure'}

- [Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/Cadilahc_05112026120755_NewspaperPublication.pdf)
- [Zydus Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Cadilahc_05112026191417_Investorconference05112026.pdf)
- [Zydus Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Cadilahc_05112026192606_Investorconference05112026_1.pdf)
- [Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026121711_OutcomeofBM.pdf)
- [Zydus Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on November 04, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026122736_SEIntimationStatutoryAuditors.pdf)
- [Zydus Lifesciences Limited has informed the Exchange regarding Change in Auditors of the company. |SUBJECT: Change in Auditors](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026123245_SEIntimationStatutoryAuditors.pdf)
- [Zydus Lifesciences Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026123450_Investorpresentation.pdf)
- [Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 04, 2026, titled "Press release". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026123914_PressRelease.pdf)
- [Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026150149_Newspaperadvertisement04112026.pdf)
- [Zydus Lifesciences Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026191430_AudioLink.pdf)

### Fundamentals

Zydus Lifesciences demonstrates a divergence between long-term profitability and recent operational efficiency. While the company maintains strong historical returns on equity (21% over 3–5 years) and compounded profit growth of 32% over three years, recent quarters show sequential pressure. In Q2 FY2026-27, revenue fell slightly to ₹7,910 crore from ₹8,017 crore in Q1, while expenses rose to ₹6,807 crore. This compressed Profit Before Tax to ₹1,234 crore from ₹1,307 crore, with finance costs increasing sequentially to ₹187 crore.

The balance sheet reflects an aggressive expansion phase. Total borrowings surged to ₹12,496 crore by Mar 2026, up from ₹804 crore in Mar 2024, driving fixed assets to ₹24,106 crore. Consequently, cash conversion has deteriorated; CFO/EBITDA share dropped to 44% in Mar 2026 from 122% in Mar 2025, and the cash conversion cycle lengthened to 212 days. Liquidity is tightening as cash reserves fell to ₹669 crore by Sep 2026, while current liabilities nearly doubled to ₹18,024 crore, largely due to borrowings rising to ₹9,143 crore. Promoter holding remains stable at ~75%, but the shift toward debt-funded growth requires monitoring against earnings recovery.

- Sequential margin compression: Q2 FY2026-27 revenue decreased to ₹7,910 crore while expenses increased to ₹6,807 crore, reducing PBT to ₹1,234 crore.
- Debt-fueled expansion: Borrowings grew to ₹12,496 crore by Mar 2026 (from ₹804 crore in Mar 2024), supporting fixed asset growth to ₹24,106 crore.
- Cash flow deterioration: Cash conversion ratio fell to 44% in Mar 2026, and cash reserves declined to ₹669 crore by Sep 2026 despite high operating profits.
- Liquidity pressure: Current liabilities doubled to ₹18,024 crore by Sep 2026, driven by current borrowings rising to ₹9,143 crore.

### Bull Case

Zydus Lifesciences presents a conditional upside case driven by robust top-line expansion and strategic pipeline progress, despite near-term profit compression. Revenue from operations surged 29.2% year-on-year to ₹7,909.6 crore in the September quarter, with the pharmaceuticals segment contributing 83% of sales. This growth was further bolstered by a 76% surge in consumer wellness sales and strong international market performance. Concurrently, the company is advancing its specialty drug pipeline, including a US FDA-accepted pembrolizumab biosimilar application and Saroglitazar in Phase III trials. Technical indicators support this constructive view, with both daily and monthly Supertrend signals remaining bullish. The stock has delivered a +30.9% year-to-date return as of November 6, 2026, trading near resistance levels at ₹1,201.95 and ₹1,207.93. While rising expenses, including ₹657.3 crore in R&D, have weighed on net profit (down 26.6% to ₹925.5 crore), the significant revenue growth and technical strength suggest potential for upward momentum if expense management improves.

- Revenue grew 29.2% YoY to ₹7,909.6 crore in Q2FY27, driven by an 83% share from pharmaceuticals and a 76% surge in consumer wellness sales.
- Technical structure remains bullish across daily and monthly timeframes, with the stock up +30.9% year-to-date and trading near resistance at ₹1,201.95.
- Pipeline advancement includes a US FDA-accepted pembrolizumab biosimilar application and Saroglitazar progressing through Phase III trials.
- Net profit fell 26.6% to ₹925.5 crore due to higher total expenses (₹6,806.6 crore) and ₹657.3 crore in R&D spending, highlighting a margin pressure condition.

- [Accumulate Zydus Lifesciences; target of Rs 1191: Prabhudas Lilladher](https://www.moneycontrol.com/news/business/stocks/accumulate-zydus-lifesciences-target-of-rs-1191-prabhudas-lilladher-14072576.html)
- [Buy Zydus Lifesciences; target of Rs 1400: Choice Institutional Equities](https://www.moneycontrol.com/news/business/stocks/buy-zydus-lifesciences-target-of-rs-1400-choice-institutional-equities-14071060.html)
- [Zydus Lifesciences Q2 net profit falls 26.6% to Rs 925.5 crore](https://economictimes.indiatimes.com/markets/stocks/earnings/zydus-lifesciences-q2-net-profit-falls-26-6-to-rs-925-5-crore/articleshow/135555960.cms)
- [Zydus Q2 profit falls 27% despite 29% revenue growth; consumer wellness sales surge 76%](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-q2-profit-falls-27-despite-29-revenue-growth-consumer-wellness-sales-surge-76/articleshow/135541093.cms)
- [Diwali 2026: Stocks to buy for Samvat 2083: Adani Energy, Coforge, PNB, Zydus, KDDL - 5 shares for Muhurat Trading](https://www.livemint.com/market/stock-market-news/diwali-2026-stocks-to-buy-for-samvat-2083-adani-energy-coforge-pnb-zydus-kddl-5-shares-for-muhurat-trading-11793785141234.html)
- [Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/Cadilahc_05112026120755_NewspaperPublication.pdf)
- [Zydus Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Cadilahc_05112026191417_Investorconference05112026.pdf)
- [Zydus Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Cadilahc_05112026192606_Investorconference05112026_1.pdf)
- [Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026121711_OutcomeofBM.pdf)
- [Zydus Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on November 04, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026122736_SEIntimationStatutoryAuditors.pdf)

### Bear Case

Zydus Lifesciences reported a divergence in its Q2FY27 results, where revenue growth failed to translate into profit expansion. Consolidated net profit fell 26.6% to ₹925.5 crore despite a 29.2% year-on-year increase in revenue from operations to ₹7,909.6 crore. This margin compression was driven by a sharp rise in total expenses to ₹6,806.6 crore, including ₹657.3 crore in research and development spending. While the pharmaceuticals segment remains dominant at 83% of sales, the company’s EBITDA declined by 6%, indicating that cost pressures are currently outpacing top-line gains. On the market side, the stock is trading near immediate resistance levels, with the daily close of ₹1,197.9 sitting just below the ₹1,201.95 pivot resistance. The technical setup shows an ADX of 10.5 on the daily timeframe, suggesting weak trend momentum despite the bullish supertrend signal.

- Profit contraction: Net profit fell 26.6% to ₹925.5 crore in Q2FY27, contrasting with 29.2% revenue growth, as total expenses surged to ₹6,806.6 crore.
- Margin pressure: EBITDA declined 6% due to rising operational costs, including ₹657.3 crore in R&D spend, highlighting execution challenges in maintaining profitability.
- Technical resistance: The stock closed at ₹1,197.9, testing immediate resistance at ₹1,201.95 (0.34% above), with low daily ADX (10.5) indicating weak underlying trend strength.

- [Accumulate Zydus Lifesciences; target of Rs 1191: Prabhudas Lilladher](https://www.moneycontrol.com/news/business/stocks/accumulate-zydus-lifesciences-target-of-rs-1191-prabhudas-lilladher-14072576.html)
- [Buy Zydus Lifesciences; target of Rs 1400: Choice Institutional Equities](https://www.moneycontrol.com/news/business/stocks/buy-zydus-lifesciences-target-of-rs-1400-choice-institutional-equities-14071060.html)
- [Zydus Lifesciences Q2 net profit falls 26.6% to Rs 925.5 crore](https://economictimes.indiatimes.com/markets/stocks/earnings/zydus-lifesciences-q2-net-profit-falls-26-6-to-rs-925-5-crore/articleshow/135555960.cms)
- [Zydus Q2 profit falls 27% despite 29% revenue growth; consumer wellness sales surge 76%](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-q2-profit-falls-27-despite-29-revenue-growth-consumer-wellness-sales-surge-76/articleshow/135541093.cms)
- [Diwali 2026: Stocks to buy for Samvat 2083: Adani Energy, Coforge, PNB, Zydus, KDDL - 5 shares for Muhurat Trading](https://www.livemint.com/market/stock-market-news/diwali-2026-stocks-to-buy-for-samvat-2083-adani-energy-coforge-pnb-zydus-kddl-5-shares-for-muhurat-trading-11793785141234.html)
- [Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/Cadilahc_05112026120755_NewspaperPublication.pdf)
- [Zydus Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Cadilahc_05112026191417_Investorconference05112026.pdf)
- [Zydus Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Cadilahc_05112026192606_Investorconference05112026_1.pdf)
- [Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026121711_OutcomeofBM.pdf)
- [Zydus Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on November 04, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026122736_SEIntimationStatutoryAuditors.pdf)

### FAQs

**How did Zydus Lifesciences perform financially in Q2FY27, and what drove the results?**

For the quarter ended September 30, 2026, revenue from operations rose 29.2% to ₹7,909.6 crore, driven by international markets and a 76% surge in consumer wellness sales. However, consolidated net profit fell 26.6% to ₹925.5 crore because total expenses increased sharply to ₹6,806.6 crore, including ₹657.3 crore in research and development spending.

**What recent corporate actions and pipeline developments should investors monitor?**

The company completed the acquisition of Sterling Biotech’s API Business on November 2, 2026, and extinguished 8,730,158 equity shares via buyback in June 2026 for ₹11,063 million. Pipeline updates include US FDA acceptance of a pembrolizumab biosimilar application and Saroglitazar progressing through Phase III trials.

- [Accumulate Zydus Lifesciences; target of Rs 1191: Prabhudas Lilladher](https://www.moneycontrol.com/news/business/stocks/accumulate-zydus-lifesciences-target-of-rs-1191-prabhudas-lilladher-14072576.html)
- [Buy Zydus Lifesciences; target of Rs 1400: Choice Institutional Equities](https://www.moneycontrol.com/news/business/stocks/buy-zydus-lifesciences-target-of-rs-1400-choice-institutional-equities-14071060.html)
- [Zydus Lifesciences Q2 net profit falls 26.6% to Rs 925.5 crore](https://economictimes.indiatimes.com/markets/stocks/earnings/zydus-lifesciences-q2-net-profit-falls-26-6-to-rs-925-5-crore/articleshow/135555960.cms)
- [Zydus Q2 profit falls 27% despite 29% revenue growth; consumer wellness sales surge 76%](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-q2-profit-falls-27-despite-29-revenue-growth-consumer-wellness-sales-surge-76/articleshow/135541093.cms)
- [Diwali 2026: Stocks to buy for Samvat 2083: Adani Energy, Coforge, PNB, Zydus, KDDL - 5 shares for Muhurat Trading](https://www.livemint.com/market/stock-market-news/diwali-2026-stocks-to-buy-for-samvat-2083-adani-energy-coforge-pnb-zydus-kddl-5-shares-for-muhurat-trading-11793785141234.html)
- [Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/Cadilahc_05112026120755_NewspaperPublication.pdf)
- [Zydus Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Cadilahc_05112026191417_Investorconference05112026.pdf)
- [Zydus Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Cadilahc_05112026192606_Investorconference05112026_1.pdf)
- [Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026121711_OutcomeofBM.pdf)
- [Zydus Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on November 04, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026122736_SEIntimationStatutoryAuditors.pdf)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Strong Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹1,189.97
- Risk regime: Price Risk Currently Contained

### Support levels
- 968.3187499999999
- 942.25
- 939.4490478515625

### Resistance levels
- 1201.95
- 1232.1
- 1207.9333333333334

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.41% |
| return_10 | +6.07% |
| return_1m | +3.31% |
| return_1y | +27.89% |
| return_20 | +7.72% |
| return_3m | +8.11% |
| return_5 | -3.82% |
| return_6m | +27.60% |
| return_since_start | +23.01% |
| return_ytd | +30.91% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -18.64% |
| annualized_volatility | +24.60% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Zydus Lifesciences Limited Q2 FY2026-27: Revenue up 29%, profit down 25%

Revenue from operations rose 29.2% year on year to ₹7,909.6 crore in Q2 FY2026-27, but eased 1.3% from the June quarter. Profit for the period fell 25.1% year on year to ₹927.7 crore, while operating cash flow of ₹3,162.3 crore was more than offset by investing outflows, leaving free cash flow negative at ₹967.1 crore.

## Revenue eased after three quarters of growth

Revenue from operations was ₹7,909.6 crore, compared with ₹8,017 crore in Q1 FY2026-27 and ₹6,123.2 crore in Q2 FY2025-26. The sequential decline followed three quarters of growth, from ₹6,864.5 crore in Q3 FY2025-26 to ₹7,587 crore in Q4 and ₹8,017 crore in Q1 FY2026-27.

Total expenses were ₹6,806.6 crore, marginally above ₹6,798.3 crore in Q1 and 50.9% higher than ₹4,510.6 crore a year earlier.

## Profit declined year on year and sequentially

Profit before exceptional items and tax was ₹1,232.9 crore, down 6.9% from Q1 FY2026-27 and 28.4% from Q2 FY2025-26. A ₹1.3 crore exceptional gain, compared with an ₹18.2 crore charge in Q1, brought profit before tax to ₹1,234.2 crore, down 5.5% sequentially and 26.9% year on year.

Tax expense was ₹334 crore, versus ₹354.2 crore in Q1. Current tax rose to ₹498.7 crore from ₹375.9 crore, while deferred tax was a credit of ₹164.7 crore, compared with a credit of ₹21.7 crore in Q1. Profit from continuing operations was ₹900.2 crore. Including ₹27.5 crore of share of profit from associates and joint ventures, total profit for the period was ₹927.7 crore: ₹925.5 crore attributable to owners of the parent and ₹2.2 crore to non-controlling interests.

## Finance costs rose

Finance costs increased 19.9% sequentially to ₹187 crore from ₹156 crore in Q1 FY2026-27. Noncurrent borrowings were ₹4,106.2 crore at 30 September 2026, up from ₹3,188 crore at 31 March 2026.

## Investing outflows exceeded operating cash generation

Cash flow from operating activities was ₹3,162.3 crore in Q2, while cash flow from investing activities was negative ₹4,129.4 crore. Free cash flow was negative ₹967.1 crore, and financing cash flow was positive ₹774.1 crore.

At 30 September 2026, property, plant and equipment stood at ₹9,276.2 crore, compared with ₹9,230.7 crore at 31 March 2026. Capital work in progress increased to ₹1,635.8 crore from ₹1,165.7 crore, while noncurrent investments rose to ₹3,451.9 crore from ₹597.5 crore.

## Balance sheet and liquidity

Total assets were ₹55,606.9 crore at 30 September 2026, up from ₹52,406.6 crore at 31 March 2026. Total equity was ₹30,322.8 crore; equity attributable to owners of the parent was ₹27,817.3 crore, compared with ₹27,111.4 crore at 31 March.

Inventories increased to ₹6,882.2 crore from ₹5,628.1 crore, while current trade receivables declined to ₹4,380.7 crore from ₹5,415.7 crore. Cash and cash equivalents were ₹669.2 crore, down from ₹855.2 crore, and current investments fell to ₹3,664.1 crore from ₹5,775.8 crore. Current borrowings were ₹9,143.4 crore, compared with ₹8,581.5 crore at 31 March; noncurrent borrowings were ₹4,106.2 crore, versus ₹3,188 crore.

## EPS

Basic and diluted EPS from continuing operations were both ₹9.28 in Q2 FY2026-27, compared with ₹9.35 in Q1 and ₹12.51 in Q2 FY2025-26. Trailing twelve-month EPS was ₹41.64.

## Key Takeaway

Revenue remained well above its year-earlier level but slipped sequentially, while profit and EPS declined both year on year and from Q1. Negative free cash flow, alongside higher capital work in progress and noncurrent investments, puts cash generation and funding alongside earnings as key features of the quarter.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q1
- As of: 2026-06-30
- Promoter holding: +75.01%
- FII holding: +6.89%
- DII holding: +11.27%
- Mutual fund holding: +5.12%
- Retail holding: +4.71%
- Promoter pledged: +0.00%

### Major reported shareholders

- Zydus Family Trust (Pankaj R. Patel, Pritiben P. Patel and Sharvil P. Patel-Trustees) — +74.98% (Trusts)
- Life Insurance Corporation Of India — +5.41%
- Parag Parikh Flexi Cap Fund — +2.02%
- Kotak Flexicap Fund — +1.19%
- Arati Rajiv Mehta — +0.01%

## Official filings

- 2026-11-07 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_07112026151831_IntimationofPostResultsEarningsCallTranscript04112026.pdf)
- 2026-11-06 — Press Release: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_06112026190130_PressRelease06112026.pdf)
- 2026-11-05 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_05112026120755_NewspaperPublication.pdf)
- 2026-11-05 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_05112026191417_Investorconference05112026.pdf)
- 2026-11-05 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_05112026192606_Investorconference05112026_1.pdf)
- 2026-11-04 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026121711_OutcomeofBM.pdf)
- 2026-11-04 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026122736_SEIntimationStatutoryAuditors.pdf)
- 2026-11-04 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026123245_SEIntimationStatutoryAuditors.pdf)
- 2026-11-04 — Earnings Presentation: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026123450_Investorpresentation.pdf)
- 2026-11-04 — Press Release: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026123914_PressRelease.pdf)
- 2026-11-04 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026150149_Newspaperadvertisement04112026.pdf)
- 2026-11-04 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_04112026191430_AudioLink.pdf)
- 2026-11-04 — Financial Results Filing: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1753077_04112026073431_WEB.xml)
- 2026-11-04 — Financial Results Filing: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1753074_04112026073401_WEB.xml)
- 2026-11-02 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_02112026124012_Zydus_SBL_API_BTA_closing.pdf)
- 2026-11-02 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_1852_WebXMLFile_20261102_131308439.xml)
- 2026-10-31 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_31102026192646_SEIntimation_changesinSeniorManagement.pdf)
- 2026-10-31 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_1852_WebXMLFile_20261031_193515210.xml)
- 2026-10-30 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_30102026132831_Newspaperadvertisement30102026.pdf)
- 2026-10-24 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_24102026112911_InvestorCall24102026.pdf)
- 2026-10-21 — Press Release: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_21102026110803_PressRelease21102026.pdf)
- 2026-10-21 — Press Release: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_21102026182006_PressRelease211020261.pdf)
- 2026-10-19 — Board Meeting Notice: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_19102026120651_IntimationofBMNotice04112026.pdf)
- 2026-10-19 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_1852_WebXMLFile_20261019_122044007.xml)
- 2026-10-19 — Board Meeting Notice: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_1852_WebXMLFile_20261019_122044007.xml)

## News and market events

- 2026-11-06 — CNBC-TV18: **Zydus Lifesciences' Saroglitazar shows higher MASH resolution rates than placebo in phase 2b trial** — Zydus Lifesciences reported that its investigational drug saroglitazar achieved higher rates of steatohepatitis resolution without worsening fibrosis compared to placebo in a Phase 2b trial involving adults with MASH and stage F2–F3 fibrosis. The study found that 39.1% of patients on the 4 mg dose and 32.4% on the 2 mg dose met the primary endpoint, versus 13.7% on placebo, while secondary endpoints for fibrosis improvement did not reach statistical significance. These results will be presented at The Liver Meeting 2026, with researchers noting the drug's potential to address both liver diseas — [Source](https://www.cnbctv18.com/market/stocks/zydus-lifesciences-share-price-saroglitazar-shows-higher-mash-resolution-rates-than-placebo-in-phase-2b-trial-20029270.htm)
- 2026-11-06 — MONEYCONTROL: **Accumulate Zydus Lifesciences; target of Rs 1191: Prabhudas Lilladher** — Prabhudas Lilladher has issued an 'Accumulate' recommendation for Zydus Lifesciences, setting a price target of Rs 1191. The note suggests the stock is positioned for potential upside from its current levels. — [Source](https://www.moneycontrol.com/news/business/stocks/accumulate-zydus-lifesciences-target-of-rs-1191-prabhudas-lilladher-14072576.html)
- 2026-11-05 — MONEYCONTROL: **Buy Zydus Lifesciences; target of Rs 1400: Choice Institutional Equities** — Choice Institutional Equities has issued a 'Buy' recommendation for Zydus Lifesciences, setting a target price of Rs 1400. The note was published by Moneycontrol on November 5, 2026. — [Source](https://www.moneycontrol.com/news/business/stocks/buy-zydus-lifesciences-target-of-rs-1400-choice-institutional-equities-14071060.html)
- 2026-11-05 — Economic Times: **Zydus Lifesciences Q2 net profit falls 26.6% to Rs 925.5 crore** — Zydus Lifesciences reported a 26.6% decline in consolidated net profit to ₹925.5 crore for the September quarter, weighed down by a sharp rise in total expenses to ₹6,806.6 crore. Despite the profit drop, revenue from operations increased by 29.2% to ₹7,909.6 crore, with the pharmaceuticals segment accounting for 83% of sales. — [Source](https://economictimes.indiatimes.com/markets/stocks/earnings/zydus-lifesciences-q2-net-profit-falls-26-6-to-rs-925-5-crore/articleshow/135555960.cms)
- 2026-11-04 — Economic Times: **Zydus Q2 profit falls 27% despite 29% revenue growth; consumer wellness sales surge 76%** — Zydus Lifesciences reported a 29% year-on-year revenue increase to Rs 7,909 crore for Q2FY27, driven by strong performance in international markets and a 76% surge in consumer wellness sales. However, net profit fell 27% to Rs 925 crore and EBITDA declined 6%, primarily due to rising expenses including Rs 657.3 crore in research and development spending. The company continues to advance its specialty drug pipeline, with the US FDA accepting a pembrolizumab biosimilar application and Saroglitazar progressing through Phase III trials. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-q2-profit-falls-27-despite-29-revenue-growth-consumer-wellness-sales-surge-76/articleshow/135541093.cms)
- 2026-11-04 — Mint: **Diwali 2026: Stocks to buy for Samvat 2083: Adani Energy, Coforge, PNB, Zydus, KDDL - 5 shares for Muhurat Trading** — Nuvama Wealth identifies improving risk-reward prospects for Indian equities in Samvat 2083, citing attractive valuations, extreme bearish foreign-investor positioning, and potential global catalysts. The brokerage's Diwali stock picks include Adani Energy Solutions, Coforge, KDDL, Punjab National Bank, and Zydus Lifesciences, selected based on their technical structures and potential for further gains. — [Source](https://www.livemint.com/market/stock-market-news/diwali-2026-stocks-to-buy-for-samvat-2083-adani-energy-coforge-pnb-zydus-kddl-5-shares-for-muhurat-trading-11793785141234.html)
- 2026-11-04 — MONEYCONTROL: **Zydus Lifesciences Q2 net profit falls 27% as expenses outpace revenue growth; shares decline 3.5%** — Zydus Lifesciences reported a 27% decline in its Q2 net profit, attributing the drop to expenses outpacing revenue growth. Consequently, the company's shares fell by 3.5%. — [Source](https://www.moneycontrol.com/news/business/markets/zydus-lifesciences-q2-net-profit-falls-27-as-expenses-outpace-revenue-growth-shares-decline-3-5-14069455.html)
- 2026-11-04 — IANSLIVE.IN: **Zydus Lifesciences Q2 net profit falls 26 pc to Rs 925 crore; shares fall over 4 pc** — Zydus Lifesciences reported a 26.6% year-on-year decline in consolidated net profit to Rs 925.5 crore for the July-September quarter of FY27, despite a 29% revenue growth to Rs 7,910 crore. The company's EBITDA margin contracted significantly to 23.95% from 32.9% in the prior year period, while research and development investment accounted for 8.3% of revenue. Following the earnings release, Zydus Lifesciences shares fell over 4%, trading at Rs 1,182.05. — [Source](https://ianslive.in/zydus-lifesciences-q2-net-profit-falls-26-pc-to-rs-925-crore-shares-fall-over-4-pc--20261104135740)
- 2026-11-04 — CNBC-TV18: **Zydus Lifesciences Q2 Results: Shares fall after profit drops 27%, margins contract** — Zydus Lifesciences shares fell over 3% after the company reported a 26.6% decline in Q2 FY27 net profit to ₹925.5 crore, despite a 29.2% year-on-year revenue increase to ₹7,910 crore. The sharp drop in profitability was accompanied by a significant contraction in EBITDA margins to 24% from 33% in the prior year period. While revenue growth was driven by strong performance in North America and India formulations businesses, the company highlighted its strategic shift toward a specialty-led portfolio with the upcoming US launch of Saroglitazar. — [Source](https://www.cnbctv18.com/market/zydus-lifesciences-q2-results-shares-fall-after-profit-drops-margins-contract-20026812.htm)
- 2026-11-04 — Mint: **Top stocks to watch today:  BSE, Nykaa, NSE, SBI, IEX shares in focus on Wednesday, 4 Nov | Full list** — The Indian stock market is expected to open lower on November 4, breaking a four-session winning streak, as GIFT Nifty signals a weak start for domestic benchmarks. Several stocks including BSE, Nykaa, Lenskart, NSE, SBI, and IEX are in focus due to scheduled Q2FY27 earnings releases and operational updates. Key reported results include a 23% YoY rise in NSE's PAT, a 14% growth in SBI's standalone net profit, and a 130% jump in MCX's consolidated net profit. — [Source](https://www.livemint.com/market/stock-market-news/top-stocks-to-watch-today-bse-nykaa-nse-sbi-iex-shares-in-focus-on-wednesday-4-nov-full-list-11793755813757.html)
- 2026-11-03 — Mint: **Muhurat Trading Picks: Adani Ports, Info Edge to Kotak Bank - ICICI Sec recommends these 10 stocks to buy on Diwali** — ICICI Securities remains optimistic about Indian equities, citing strong Q2 FY27 earnings and attractive valuations despite recent market weakness, and has recommended ten stocks for Muhurat Trading. The brokerage highlighted Kotak Mahindra Bank, Adani Ports & SEZ, Info Edge, Venus Pipes, Zydus Lifesciences, Neogen Chemicals, Saregama India, Apollo Micro Systems, Ethos, and Indian Hotels as key picks with specific growth drivers and associated risks. — [Source](https://www.livemint.com/market/stock-market-news/muhurat-trading-picks-adani-ports-info-edge-to-kotak-bank-icici-sec-recommends-these-10-stocks-to-buy-on-diwali-11793700028188.html)
- 2026-10-28 — Mint: **Top 2 stocks to buy for short-term: Zydus Life, Whirlpool by Nagaraj Shetti - Check stop loss, targets** — The Nifty 50 and Sensex closed lower after a volatile session, weighed by rising oil prices. Technical analysis points to support near 22,500 and resistance around 22,800; analysts also shared short-term buy calls on Zydus Lifesciences and Whirlpool of India. — [Source](https://www.livemint.com/market/stock-market-news/top-2-stocks-to-buy-for-short-term-zydus-life-whirlpool-by-nagaraj-shetti-check-stop-loss-targets-11793185099843.html)
- 2026-10-27 — Mint: **Where are mutual funds investing your money? These stocks saw the biggest buying in September 2026. Check full list | Mint** — Mutual funds bought shares worth thousands of crores in September 2026. Reliance Industries, Swiggy and Gland Pharma led purchases across large-, mid- and small-cap categories. Check the top five stocks in each segment, according to Value Research. — [Source](https://www.livemint.com/money/personal-finance/where-are-mutual-funds-investing-your-money-these-stocks-saw-the-biggest-buying-in-september-2026-check-full-list-11793106475931.html)
- 2026-10-27 — Mint: **Top stocks to buy in F&O segment: CDSL, Zydus Lifesciences, Sun Pharma by Jay Thakkar for near-term | Check targets | Stock Market News** — The Sensex and Nifty 50 ended Tuesday slightly lower amid elevated oil prices and geopolitical uncertainty. ICICI Securities analyst Jay Thakkar said markets may stay range-bound ahead of key events, identifying support and resistance levels for the Nifty 50 and Bank Nifty. — [Source](https://www.livemint.com/market/stock-market-news/top-stocks-to-buy-in-f-o-segment-cdsl-zydus-lifesciences-sun-pharma-by-jay-thakkar-for-near-term-check-targets-11793100938012.html)
- 2026-10-26 — MONEYCONTROL: **Nomura raises Zydus Lifesciences target price to Rs 1,450, maintains 'Buy'** — Nomura raises Zydus Lifesciences target price to Rs 1,450, maintains 'Buy' Follow Us On: Stocks: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Others Trending Topics more Sensex Today Jio IPO Allotment Jamia Protest UP Polls 2027 Rahul Gandhi Infosys Share Price Aamir Khan Small Cap Stocks Cyclone Arnab Dhanush News more Business Markets Stocks India News City News Economy Mutual Funds Personal Finance IPO News Startups Markets more Home Currencies Commodities Pre-Market IPO Global Market US Markets Bonds Silver MCX Price Gold MCX Price Personal Finance more Home Loans up to 50 Lakhs Cre — [Source](https://www.moneycontrol.com/news/business/stocks/nomura-raises-zydus-lifesciences-target-price-to-rs-1-450-maintains-buy-14060085.html)
- 2026-10-23 — BUSINESSTODAY: **PNB, Indian Hotels, Zydus Lifesciences: Top stocks to trade — Check key levels, targets & stop loss** — Indian equity benchmark settled lower for another trading session, thanks to rising inflation concerns led by elevated crude oil prices and escalating West Asia conflict, weighing on the investor sentiments. — [Source](https://www.businesstoday.in/markets/stocks/story/pnb-indian-hotels-zydus-lifesciences-top-stocks-to-trade-check-key-levels-targets-stop-loss-563184-2026-10-23)
- 2026-10-21 — CNBC-TV18: **From lab to production line: Zydilac Bio bets on light-powered protein manufacturing** — A new manufacturing partnership aims to bridge the gap between biotech breakthroughs and commercial production. At its core is a platform that uses light to control protein expression, with ambitions to scale up output without building an entirely new infrastructure. — [Source](https://www.cnbctv18.com/lifestyle/healthcare/from-lab-to-production-line-zydilac-bio-bets-on-light-powered-protein-manufacturing-20016371.htm)
- 2026-10-21 — The Hindu: **Zydus Lifesciences gets USFDA nod for menopause treatment drug** — Zydus Lifesciences gains USFDA approval for Estradiol and Levonorgestrel Transdermal System, a CGT menopause patch with $45.7 million US sales potential. — [Source](https://www.thehindubusinessline.com/companies/zydus-lifesciences-gets-usfda-nod-for-menopause-treatment-drug/article71606787.ece)
- 2026-10-15 — The Hindu: **Zydus-Sunshine JV signs pact with Sri Lanka’s BOI for $20 mn pharma plant** — Zydus Sunshine to invest $20M in Sri Lanka’s Horana pharma plant, boosting local manufacturing and supply resilience for 2028 operations. — [Source](https://www.thehindu.com/business/Industry/zydus-sunshine-jv-signs-pact-with-sri-lankas-boi-for-20-mn-pharma-plant/article71587665.ece)
- 2026-10-14 — The Hindu: **Zydus’ manufacturing plant gets 5 U.S. FDA observations** — Zydus Lifesciences faces five FDA observations at its Moraiya plant after inspection, with plans to address them promptly. — [Source](https://www.thehindu.com/business/Industry/zydus-manufacturing-plant-gets-5-us-fda-observations/article71584361.ece)
- 2026-10-14 — CNBC-TV18: **Explained - Why Zydus Life is in focus and why Bernstein sees nearly 30% upside** — Of the 34 analysts that have coverage on the Zydus Life stock, 19 have a "buy" rating, nine have a "hold" rating and six have "sell" recommendation. — [Source](https://www.cnbctv18.com/market/zydus-lifesciences-share-price-usfda-moraiya-observations-bla-biosimilar-bernstein-buy-target-upside-factors-20011319.htm)
- 2026-10-13 — CNBC-TV18: **Zydus Lifesciences' USFDA inspection at Ahmedabad plant concludes with 5 observations** — Zydus Lifesciences said the USFDA inspection of its Moraiya manufacturing plant in Ahmedabad concluded on October 13 with five observations. The inspection took place from October 5 to October 13, and the company said it would work with the USFDA to address the observations expeditiously. — [Source](https://www.cnbctv18.com/market/stocks/zydus-lifesciences-share-price-usfda-inspection-at-ahmedabad-plant-concludes-with-5-observations-20011161.htm)
- 2026-10-06 — The Hindu: **Zydus launches in U.S. MSN Labs generic of Bayer’s PAH drug** — Zydus Lifesciences and MSN Labs launch US generic Riociguat (Bayer’s Adempas) for PAH and CTEPH, first-to-market. — [Source](https://www.thehindu.com/business/Industry/zydus-launches-in-us-msn-labs-generic-of-bayers-pah-drug/article71552208.ece)
- 2026-10-06 — Economic Times: **Stocks in news: Vedanta, Kotak Mahindra Bank, Marico, Axis Bank, Trent and Zydus Lifesciences** — Indian equity markets showed signs of recovery on Monday after softer-than-expected US jobs data was released. The Nifty 50 index ended the session up, suggesting improved investor confidence. Investors are watching key corporate updates from companies like Vedanta and Kotak Mahindra Bank for future trends. Firms reported various operational advancements and financial performance improvements for the quarter. The overall sentiment in the market remains cautiously optimistic amid external economi... — [Source](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-vedanta-kotak-mahindra-bank-marico-axis-bank-trent-and-zydus-lifesciences/articleshow/134712004.cms)
- 2026-10-01 — MONEYCONTROL: **Buzzing Stocks: SML Mahindra, M&M slip on monthly sales; Highway Infra gains 8% on contract win** — Buzzing Stocks — [Source](https://www.moneycontrol.com/news/business/markets/buzzing-stocks-sml-mahindra-m-m-slip-on-monthly-sales-highway-infra-gains-8-on-contract-win-14042240.html)

## Business profile

**Strategic vision:** Global healthcare provider developing and marketing pharmaceutical products.

### Business segments
- **Pharmaceuticals and Healthcare:** Engaged in research, development, manufacturing, and marketing of active pharmaceutical ingredients, formulations, vaccines, biosimilars, and complex products.
- **Animal Health:** Develops and markets products for the animal health sector.
- **Wellness Products:** Offers a range of wellness products aimed at improving overall health.

### Competitive strengths
- Fully integrated global healthcare provider
- Comprehensive capabilities across the pharmaceutical value chain
- Significant global manufacturing footprint

## Related stocks

- [Alkem Laboratories Limited (Healthcare)](https://faxioms.com/stocks/alkem) — +2.06%
- [Aurobindo Pharma Limited (Healthcare)](https://faxioms.com/stocks/auropharma) — +0.84%
- [Cipla Limited (Healthcare)](https://faxioms.com/stocks/cipla) — +0.49%
- [Dr. Reddy's Laboratories Limited (Healthcare)](https://faxioms.com/stocks/drreddy) — +0.51%
- [Glenmark Pharmaceuticals Limited (Healthcare)](https://faxioms.com/stocks/glenmark) — +4.36%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/zyduslife
Markdown representation: https://faxioms.com/stocks/zyduslife?render=md